NCT01636310

Brief Summary

The proposed clinical studies will analyze the interactions between nicotine, alterations in endocrine hormones, mood and cardiovascular measures. They also intend to examine the contribution of gender and menstrual cycle phase. These studies hypothesize that this novel focus on nicotine's rapid hormonal, cardiovascular and subjective effects will be important for developing novel biologic approaches to treatment for nicotine abuse and dependence as well as advancing our understanding of the neurobiology of nicotine reinforcement.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Trial recruitment is currently suspended
Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2005

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2005

Completed
6.6 years until next milestone

First Submitted

Initial submission to the registry

June 21, 2012

Completed
19 days until next milestone

First Posted

Study publicly available on registry

July 10, 2012

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

January 15, 2013

Status Verified

January 1, 2013

Enrollment Period

11 years

First QC Date

June 21, 2012

Last Update Submit

January 14, 2013

Conditions

Outcome Measures

Primary Outcomes (2)

  • Effects of Nicotine on the hypothalamic-pituitary-adrenal (HPA) axis

    The investigators are examining the effects of smoked nicotine on serum nicotine levels and serum/plasma hormone levels.

    From baseline to study completion (approximatley 8 months for females)

  • Effects of Nicotine on the hypothalamic-pituitary-gonadal (HPG) axis

    The investigators are examining the effects of smoked nicotine on serum level nicotine and serum/plasma hormone levels.

    From baseline to study completion (approximately 8 months for females)

Secondary Outcomes (2)

  • Effects of Nicotine on Mood States on the Visual Analog Scale

    From baseline to study completion (approximately 8 months for females)

  • Effects of Nicotine on cardiovascular measures

    From baseline to study completion (approximately 8 months for females)

Study Arms (2)

Female Smokers (Mid-Luteal Phase; cycle days 18-22)

ACTIVE COMPARATOR
Other: Nicotine

Female Smokers (Early Follicular Phase; cycle days 4-8)

ACTIVE COMPARATOR
Other: Nicotine

Interventions

Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.

Female Smokers (Early Follicular Phase; cycle days 4-8)Female Smokers (Mid-Luteal Phase; cycle days 18-22)

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Women between the ages of 18 and 40 who currently smoke at least 15 cigarettes every day, and who fulfill DSM-IV diagnostic criteria for nicotine dependence (305.10) will be eligible for participation.
  • No evidence of clinically significant disease based upon complete medical history and physical examination by a qualified physician.
  • Absence of DSM-IV Axis I Disorders other than nicotine dependence (305.10) as measured by the Structured Clinical Interview (SCID).
  • Routine laboratory blood tests including complete blood count, electrolytes, BUN and creatinine, liver function test, hepatitis panel and urinalysis will be performed. Laboratory parameters must be within the normal range. HBsAg must be negative but study participants who have hepatitis serology consistent with previous exposure to Hepatitis A, Hepatitis B, or Hepatitis C, but who do not have clinical and biochemical evidence of acute infection, will be acceptable.
  • Hematocrit levels ≥ 35%.
  • Serum pregnancy test (hCG beta subunit) results must be negative within 24 hrs of the study day.
  • Normal ECG.
  • A mean Body Mass Index (ratio of weight (W) to height (H) squared; W/H2=kg/m2) will be calculated. Women with a mean Body Mass Index (BMI) between 18.0-27.0 will be accepted.
  • Study participants must be able to read, understand instructions and provide a valid informed consent.

You may not qualify if:

  • Women with any lifetime DSM-IV Axis I disorder other than nicotine dependence will be excluded.
  • Women who are pregnant as determined by laboratory testing for serum beta hCG will be excluded.
  • Women who use hormonal contraceptive medications will not be accepted for participation because this would confound the hormonal measures.
  • Women with clinically significant medical disorders will be excluded.
  • A mean Body Mass Index (ratio of weight (W) to height (H) squared; W/H2=kg/m2) will be calculated. Women with a mean Body Mass Index (BMI) outside of the range of 18.0-27.0 will be excluded.
  • Treatment seeking study participants will not be selected but will be referred to local smoking cessation programs.
  • Women taking any OTC medications on a regular basis (with the exception of multivitamin formulas) or prescription medications will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alcohol and Drug Abuse Research Center at McLean Hospital

Belmont, Massachusetts, 02478, United States

Location

MeSH Terms

Conditions

Tobacco Use Disorder

Interventions

Nicotine

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Solanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsPyridinesHeterocyclic Compounds, 1-Ring

Study Officials

  • Nancy K Mello, PhD

    Mclean Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Alcohol and Drug Abuse Research Center & Professor of Psychology (Neuroscience), Harvard Medical School

Study Record Dates

First Submitted

June 21, 2012

First Posted

July 10, 2012

Study Start

December 1, 2005

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

January 15, 2013

Record last verified: 2013-01

Locations